Aurelie Dutour

28 Rue Laennec
Lyon, 69373, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.

Journal: International journal of molecular sciences
Published: January 18, 2026

Prognostic Impact of CD206+ M2-Like Macrophages in Canine Appendicular Osteosarcoma.

Prognostic Impact of CD206+ M2-Like Macrophages in Canine Appendicular Osteosarcoma.

Journal: Veterinary and comparative oncology
Published: September 16, 2025

Bimodality imaging as a companion to evaluate antitumour efficacy of TH-302 in experimental chondrosarcoma.

Bimodality imaging as a companion to evaluate antitumour efficacy of TH-302 in experimental chondrosarcoma.

Journal: EJNMMI research
Published: May 26, 2025

Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.

Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.

Journal: Neuro-oncology
Published: January 10, 2025

Microenvironment matters: insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy.

Microenvironment matters: insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy.

Journal: Cancer metastasis reviews
Published: October 14, 2024

BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas.

BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas.

Journal: eLife
Published: October 07, 2024

Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.

Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.

Journal: ESMO open
Published: September 19, 2024

Author Correction: Cancer characterization using light backscattering spectroscopy and quantitative ultrasound: an ex vivo study on sarcoma subtypes.

Author Correction: Cancer characterization using light backscattering spectroscopy and quantitative ultrasound: an ex vivo study on sarcoma subtypes.

Journal: Scientific reports
Published: March 19, 2024

Author Correction: Cancer characterization using light backscattering spectroscopy and quantitative ultrasound: an ex vivo study on sarcoma subtypes.

Author Correction: Cancer characterization using light backscattering spectroscopy and quantitative ultrasound: an ex vivo study on sarcoma subtypes.

Journal: Scientific reports
Published: November 14, 2023

Correction: The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma.

Correction: The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma.

Journal: Life science alliance
Published: November 13, 2023

Cancer characterization using light backscattering spectroscopy and quantitative ultrasound: an ex vivo study on sarcoma subtypes.

Cancer characterization using light backscattering spectroscopy and quantitative ultrasound: an ex vivo study on sarcoma subtypes.

Journal: Scientific reports
Published: July 28, 2023

A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages.

A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages.

Journal: Cancers
Published: July 21, 2023
Showing 1-12 of 27

Last Updated: 09/26/2026